[
  {
    "ts": null,
    "headline": "Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance",
    "summary": "The Harbor Small Cap Growth Fund outperformed its benchmark this quarter. Strength in Industrials and Information Technology offset relative weakness in Health Care.",
    "url": "https://finnhub.io/api/news?id=25731e3dde25e08ac24441390afa231344a8c4454cdb639770ad449c1c4ae911",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769725800,
      "headline": "Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance",
      "id": 138302472,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1330681654/image_1330681654.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Harbor Small Cap Growth Fund outperformed its benchmark this quarter. Strength in Industrials and Information Technology offset relative weakness in Health Care.",
      "url": "https://finnhub.io/api/news?id=25731e3dde25e08ac24441390afa231344a8c4454cdb639770ad449c1c4ae911"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans",
    "summary": "AbbVie (NYSE:ABBV) agreed to a three year voluntary drug affordability deal with the US government, paired with a pledge to invest $100b in R&D. The company is expanding its direct to patient drug platform and rolling out the Love in Mind™ migraine education initiative. AbbVie is also presenting new data from its aesthetics portfolio and reporting advances in early stage clinical trials. AbbVie enters this set of announcements with its shares at $218.67 and a 1 year return of 29.0%, and 5...",
    "url": "https://finnhub.io/api/news?id=a77a75a46c209f749732e9a65da56420f220075dc26b373a1f77a9bd2c23a92e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769717455,
      "headline": "AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans",
      "id": 138300060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) agreed to a three year voluntary drug affordability deal with the US government, paired with a pledge to invest $100b in R&D. The company is expanding its direct to patient drug platform and rolling out the Love in Mind™ migraine education initiative. AbbVie is also presenting new data from its aesthetics portfolio and reporting advances in early stage clinical trials. AbbVie enters this set of announcements with its shares at $218.67 and a 1 year return of 29.0%, and 5...",
      "url": "https://finnhub.io/api/news?id=a77a75a46c209f749732e9a65da56420f220075dc26b373a1f77a9bd2c23a92e"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results",
    "summary": "Healthcare ETFs draw attention as UNH climbs 4% on mixed Q4 results, a better 2026 cost outlook, and rising concerns over Medicaid pressure.",
    "url": "https://finnhub.io/api/news?id=27bd531e10f57af599efce14e8c7fc95a6357e0e878e38ba8e4ff749fdf209ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769695980,
      "headline": "Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results",
      "id": 138295596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Healthcare ETFs draw attention as UNH climbs 4% on mixed Q4 results, a better 2026 cost outlook, and rising concerns over Medicaid pressure.",
      "url": "https://finnhub.io/api/news?id=27bd531e10f57af599efce14e8c7fc95a6357e0e878e38ba8e4ff749fdf209ea"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships",
    "summary": "AbbVie (NYSE: ABBV) announced today the launch of Love in Mind™, an educational initiative that seeks to elevate the conversation about the emotional impact of living with migraine, beyond the physical symptoms, with a focus on dating and romantic relationships. Migraine is more than just a headache. It is an underdiagnosed, undertreated neurological disease that can cause debilitating pain affecting nearly 40 million Americans.1,2",
    "url": "https://finnhub.io/api/news?id=2edc1fe78062120b440de627ab7f042dc0bf12d1b826a47c7ece712163f85574",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769691600,
      "headline": "AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships",
      "id": 138294631,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced today the launch of Love in Mind™, an educational initiative that seeks to elevate the conversation about the emotional impact of living with migraine, beyond the physical symptoms, with a focus on dating and romantic relationships. Migraine is more than just a headache. It is an underdiagnosed, undertreated neurological disease that can cause debilitating pain affecting nearly 40 million Americans.1,2",
      "url": "https://finnhub.io/api/news?id=2edc1fe78062120b440de627ab7f042dc0bf12d1b826a47c7ece712163f85574"
    }
  },
  {
    "ts": null,
    "headline": "10 Highest Rated Dividend Kings For Generations Of Income",
    "summary": "Top 10 Dividend Kings ranked for reliability, dividend safety, and valueâfeaturing ABM and strict payout screens. Click for the income picks!",
    "url": "https://finnhub.io/api/news?id=06c075c19b76a9c2cc4f93a4b1963260b9df1dbd4fb5f8bc4fd89bab28aafc14",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769681421,
      "headline": "10 Highest Rated Dividend Kings For Generations Of Income",
      "id": 138295281,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411467903/image_1411467903.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Top 10 Dividend Kings ranked for reliability, dividend safety, and valueâfeaturing ABM and strict payout screens. Click for the income picks!",
      "url": "https://finnhub.io/api/news?id=06c075c19b76a9c2cc4f93a4b1963260b9df1dbd4fb5f8bc4fd89bab28aafc14"
    }
  },
  {
    "ts": null,
    "headline": "Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
    "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.",
    "url": "https://finnhub.io/api/news?id=16a3e05644a2e9488b220bfcd85a672214927ef35a68d48fb8882ffa27264901",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769657557,
      "headline": "Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
      "id": 138302008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.",
      "url": "https://finnhub.io/api/news?id=16a3e05644a2e9488b220bfcd85a672214927ef35a68d48fb8882ffa27264901"
    }
  }
]